MedTrace Logo

Trial on the Effect of Budesonide/Formoterol and Inhaled Budesonide Alone on Exercise-Induced Asthma

NCT01070888 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2021-07-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to find out if Symbicort® (budesonide/formoterol), a new combination asthma medication, is more effective than budesonide alone in controlling exercise induced asthma.

The investigators hypothesize that in children and adults who suffer from asthma and exercise induced asthma there will be less decline in lung function associated with exercise when they receive the study medication.

Conditions

  • Exercise Induced Asthma

Interventions

DRUG

Budesonide/Formoterol

Budesonide/Formoterol 160/4.5, 2 puff twice daily for 2 weeks

DRUG

Budesonide

Budesonide 180mcg, 2 puffs twice daily for 2 weeks

Sponsors & Collaborators

Principal Investigators

  • Wanda Phipatanakul, MD,MS · Boston Children's Hospital

  • Jonathan M Gaffin, MD · Boston Children's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
12 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01070888 on ClinicalTrials.gov